...million in an oversubscribed series C round co-led by GL Ventures and Temasek. New investors Oceanpine Capital...
...of the $1.4 billion acquisition of CV Therapeutics by Gilead Sciences Inc. (NASDAQ:GILD) in 2009. Oceanpine Capital...

...investment bank Bloom Burton & Co. and the Montreal-based Centre for Commercialization of Cancer Immunotherapy (C3i). Oceanpine Capital...

...the round to $123 million. The extension was led by Decheng Capital and new investor Oceanpine Capital...

...antiviral company’s long-term strategy to add Chinese investors to help it penetrate the China market. Oceanpine Capital...

...million on Oct. 9 in a series C round led by Lepu Medical. New investors Oceanpine Capital...

...from fellow new Chinese investors Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...

...Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...

...Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...